NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, Price Target & More

$60.64 -0.99 (-1.61 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$61.63

Today's Range$59.79 - $62.48

52-Week Range$42.23 - $74.70

Volume105,029 shs

Average Volume123,357 shs

Market Capitalization$717.04 million

P/E Ratio16.80

Dividend YieldN/A

Beta2.91

About ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ANIP

CUSIPN/A

Webwww.anipharmaceuticals.com

Phone218-634-3500

Debt

Debt-to-Equity Ratio1.13%

Current Ratio3.36%

Quick Ratio2.39%

Price-To-Earnings

Trailing P/E Ratio16.80

Forward P/E Ratio11.73

P/E GrowthN/A

Sales & Book Value

Annual Sales$176.84 million

Price / Sales4.02

Cash Flow$5.9335 per share

Price / Cash10.22

Book Value$14.99 per share

Price / Book4.05

Profitability

EPS (Most Recent Fiscal Year)$3.61

Net Income$-1,070,000.00

Net Margins-0.61%

Return on Equity23.41%

Return on Assets11.03%

Miscellaneous

Employees173

Outstanding Shares11,730,000

How to Become a New Pot Stock Millionaire

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings data on Tuesday, February, 27th. The specialty pharmaceutical company reported $1.08 EPS for the quarter, topping the Zacks' consensus estimate of $1.02 by $0.06. The specialty pharmaceutical company earned $47.30 million during the quarter, compared to the consensus estimate of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The firm's revenue was up 23.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.84 EPS. View ANI Pharmaceuticals' Earnings History.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $5.43-6.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.76. The company issued revenue guidance of $212-228 million, compared to the consensus revenue estimate of $219.98 million.

What price target have analysts set for ANIP?

3 Wall Street analysts have issued 12-month price objectives for ANI Pharmaceuticals' stock. Their predictions range from $56.00 to $82.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $72.6667 in the next twelve months. View Analyst Ratings for ANI Pharmaceuticals.

What are Wall Street analysts saying about ANI Pharmaceuticals stock?

Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:

1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (1/2/2018)
2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)

Who are some of ANI Pharmaceuticals' key competitors?

Some companies that are related to ANI Pharmaceuticals include ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), G1 Therapeutics (GTHX), Apellis Pharmaceuticals (APLS), Endo International (ENDP), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD), PTC Therapeutics (PTCT), Revance Therapeutics (RVNC), Mallinckrodt (MNK), WAVE Life Sciences (WVE), Epizyme (EPZM), Intra-Cellular Therapies (ITCI), Athenex (ATNX), Retrophin (RTRX) and Zai Lab (ZLAB).

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the folowing people:

Robert E. Brown Jr., Independent Chairman of the Board (Age 66)
Arthur S. Przybyl, President, Chief Executive Officer, Director (Age 60)
Stephen P. Carey, Chief Financial Officer, Vice President (Age 46)
James G. Marken, Vice President - Operations (Age 54)
Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing (Age 45)
Fred E. Holubow, Independent Director (Age 78)
Tracy L. Marshbanks Ph.D., Independent Director (Age 53)
Thomas A. Penn, Independent Director (Age 71)

Has ANI Pharmaceuticals been receiving favorable news coverage?

News coverage about ANIP stock has been trending somewhat positive on Thursday, according to Accern. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ANI Pharmaceuticals earned a news impact score of 0.07 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 45.82 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $60.64.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $717.04 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals employs 173 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]

MarketBeat Community Rating for ANI Pharmaceuticals (ANIP)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		238 (Vote Outperform)
Underperform Votes:		198 (Vote Underperform)
Total Votes:		436

MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.

ANI Pharmaceuticals (NASDAQ:ANIP) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for ANI Pharmaceuticals in the last 12 months. Their average twelve-month price target is $72.6667, suggesting that the stock has a possible upside of 19.83%. The high price target for ANIP is $82.00 and the low price target for ANIP is $56.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.67	2.67	2.67
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$72.6667	$72.6667	$71.00	$67.3333
Price Target Upside:	19.83% upside	20.31% upside	11.62% upside	12.02% upside

ANI Pharmaceuticals (NASDAQ:ANIP) Consensus Price Target History

Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/27/2018	Canaccord Genuity	Set Price Target	Buy -> Buy	$77.00 -> $82.00	High
7/4/2017	Guggenheim	Reiterated Rating	Buy	$80.00	Low
5/6/2017	Roth Capital	Set Price Target	Hold	$56.00	Low
8/5/2016	Oppenheimer	Boost Price Target	Outperform	$65.00 -> $71.00	N/A
7/19/2016	Citigroup	Upgrade	Outperform	$65.00	N/A
6/22/2016	Raymond James	Initiated Coverage	Strong-Buy	$68.00	N/A
5/24/2016	Standpoint Research	Downgrade	Buy -> Hold		N/A

(Data available from 4/19/2016 forward)

ANI Pharmaceuticals (NASDAQ:ANIP) Earnings History and Estimates Chart

Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) Earnings Estimates

Current Year EPS Consensus Estimate: $5.17 EPS
Next Year EPS Consensus Estimate: $5.41 EPS

ANI Pharmaceuticals (NASDAQ ANIP) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/27/2018	Q4 17	$1.02	$1.08	$52.55 million	$47.30 million	View	N/A
11/2/2017	Q3 2017	$0.99	$1.11	$48.12 million	$48.16 million	View	N/A
8/3/2017	Q2 2017	$0.79	$0.98	$43.20 million	$44.80 million	View	Listen
5/4/2017	Q1 2017	$0.70	$0.74	$39.63 million	$36.60 million	View	Listen
3/2/2017	Q4 2016	$1.09	$0.84	$40.98 million	$38.20 million	View	Listen
11/3/2016	Q316	$1.08	$1.09	$34.34 million	$38.53 million	View	N/A
8/4/2016	Q216	$0.77	$1.11	$27.63 million	$31.30 million	View	N/A
5/5/2016	Q116	$0.64	$0.76	$21.03 million	$20.60 million	View	N/A
2/23/2016	Q415	$0.60	$0.52	$18.13 million	$18.04 million	View	N/A
11/3/2015	Q315	$0.63	$0.80	$21.37 million	$20.00 million	View	N/A
8/4/2015	Q215	$0.54	$0.31	$20.30 million	$19.52 million	View	N/A
5/5/2015	Q115	$0.56	$0.53	$19.86 million	$18.80 million	View	N/A
2/19/2015	Q414	$0.57	$0.60	$17.98 million	$21.04 million	View	N/A
11/3/2014	Q314	$0.43	$0.59	$14.60 million	$17.40 million	View	N/A
8/4/2014	Q214	($0.01)	($0.21)	$7.95 million	$6.60 million	View	N/A
5/5/2014	Q115	$0.32	$0.33	$11.40 million	$10.90 million	View	N/A
2/27/2014	Q414		$0.35	$5.32 million	$10.53 million	View	N/A
2/18/2014	Q4 2013	$0.23	$0.35	$9.18 million	$10.53 million	View	N/A
11/7/2013			$0.16		$7.84 million	View	N/A
8/9/2013	Q2 2013		($1.26)		$6.15 million	View	N/A
5/10/2013	Q1 2013		($0.54)			View	N/A
3/1/2013	Q4 2012		($0.96)			View	N/A
11/8/2012	Q312	($0.36)	($0.27)			View	N/A
8/1/2012	Q2 2012	($2.46)	($2.18)			View	N/A
5/8/2012	Q1 2012	($2.52)	($3.24)			View	N/A
3/13/2012	Q4 2011	($3.96)	($2.16)			View	N/A
11/9/2011	Q3 2011	($5.04)	($4.39)			View	N/A
7/25/2011	Q2 2011	($6.48)	($5.76)			View	N/A
5/10/2011	Q1 2011	($5.40)	($7.20)			View	N/A
3/16/2011	Q4 2010	($5.40)	($6.48)			View	N/A
11/12/2010	Q3 2010	($5.04)	($5.76)			View	N/A
8/12/2010	Q2 2010	($3.96)	($6.12)			View	N/A
5/14/2010	Q1 2010	($3.96)	($6.84)			View	N/A
11/9/2009	Q3 2009	($5.76)	($5.79)			View	N/A
8/7/2009	Q2 2009	($5.40)	($6.12)			View	N/A
5/11/2009	Q1 2009	($5.76)	($5.40)			View	N/A
3/16/2009	Q4 2008	($8.64)	($1.80)			View	N/A
11/10/2008	Q3 2008	($7.20)	($8.64)			View	N/A
8/11/2008	Q2 2008	($5.40)	($7.92)			View	N/A
5/9/2008	Q1 2008	($4.32)	($4.68)			View	N/A
3/17/2008	Q4 2007		($2.16)			View	N/A

(Earnings results data provided by Zacks Investment Research)

ANI Pharmaceuticals (NASDAQ:ANIP) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

ANI Pharmaceuticals (NASDAQ ANIP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.10%
Institutional Ownership Percentage: 55.77%

Insider Trading History for ANI Pharmaceuticals (NASDAQ:ANIP)

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ ANIP) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2018	Daniel Raynor	Director	Sell	7,215	$60.85	$439,032.75
3/14/2018	Arthur Przybyl	Insider	Sell	40,000	$61.83	$2,473,200.00	225,706
3/14/2018	Daniel Raynor	Director	Sell	27,964	$62.24	$1,740,479.36
3/12/2018	Tracy Marshbanks	Director	Sell	64,221	$63.03	$4,047,849.63
3/8/2018	Tracy Marshbanks	Director	Sell	15,391	$63.08	$970,864.28
3/5/2018	James G Marken	SVP	Sell	4,177	$61.92	$258,639.84	66,439
3/1/2018	Robert W Schrepfer	SVP	Sell	28,652	$61.66	$1,766,682.32	41,590
8/22/2016	Arthur Przybyl	Insider	Sell	37,455	$66.97	$2,508,361.35	200,788
8/8/2016	Robert W Schrepfer	VP	Sell	12,500	$67.06	$838,250.00	17,362
12/18/2015	James G Marken	VP	Sell	3,500	$43.26	$151,410.00	45,983
11/12/2015	Arthur Przybyl	CEO	Buy	2,500	$40.95	$102,375.00	145,195
3/19/2015	James G Marken	VP	Sell	15,000	$66.50	$997,500.00
9/15/2014	Ross J Mangano	Director	Buy	3,000	$27.49	$82,470.00
9/9/2014	Arthur Przybyl	CEO	Buy	1,000	$26.50	$26,500.00
6/18/2014	James G Marken	VP	Sell	5,000	$34.28	$171,400.00
5/8/2014	Tracy Marshbanks	Director	Sell	1,381	$30.02	$41,457.62
5/7/2014	Ross Mangano	Director	Buy	2,000	$30.38	$60,760.00	23,914
3/21/2014	Tracy Marshbanks	Director	Sell	21,767	$31.42	$683,919.14
3/20/2014	Meridian Venture Partners Ii L	major shareholder	Sell	20,922	$32.12	$672,014.64
3/19/2014	Tracy Marshbanks	Director	Sell	25,358	$33.68	$854,057.44
3/18/2014	Meridian Venture Partners Ii L	major shareholder	Sell	60,540	$34.07	$2,062,597.80
3/13/2014	Meridian Venture Partners Ii L	major shareholder	Sell	87,723	$32.48	$2,849,243.04
11/7/2013	Ross J Mangano	Director	Buy	9,000	$11.27	$101,430.00
8/20/2013	Ross J Mangano	Director	Buy	10,000	$7.47	$74,700.00

(Data available from 1/1/2013 forward)

ANI Pharmaceuticals (NASDAQ ANIP) News Headlines

Source:

Date	Headline
	FDA OKs ANI Pharma's generic morphine oral solution seekingalpha.com - April 18 at 5:07 PM
	BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution www.reuters.com - April 18 at 9:01 AM
	ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution finance.yahoo.com - April 18 at 9:01 AM
	ANI Pharmaceuticals (ANIP) Now Covered by Analysts at Canaccord Genuity www.americanbankingnews.com - April 15 at 9:45 AM
	ANI Pharmaceuticals (ANIP) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - April 12 at 10:47 AM
	ANI Pharmaceuticals (ANIP) Given Buy Rating at Canaccord Genuity www.americanbankingnews.com - April 7 at 12:31 PM
	ANI Pharma (ANIP) Buys 23 ANDAs from IDT Australia, Ltd. www.streetinsider.com - April 4 at 3:39 PM
	ANI Acquires 23 ANDAs from IDT Australia, Ltd. finance.yahoo.com - April 4 at 9:04 AM
	ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - April 4 at 1:40 AM
	ANI Pharmaceuticals (ANIP) Downgraded to "Hold" at ValuEngine www.americanbankingnews.com - April 3 at 7:34 PM
	Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company? finance.yahoo.com - April 3 at 4:54 PM
	ANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClub www.americanbankingnews.com - March 26 at 5:58 PM
	Canaccord Genuity Analysts Give ANI Pharmaceuticals (ANIP) a $82.00 Price Target www.americanbankingnews.com - March 24 at 5:43 PM
	ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 7,215 Shares www.americanbankingnews.com - March 19 at 7:30 PM
	Where ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Earnings Growth Stands Against Its Industry finance.yahoo.com - March 16 at 9:11 AM
	ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 27,964 Shares www.americanbankingnews.com - March 14 at 7:11 PM
	ANI Pharmaceuticals Inc (ANIP) Insider Sells $2,473,200.00 in Stock www.americanbankingnews.com - March 14 at 7:10 PM
	Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock? www.zacks.com - March 14 at 9:44 AM
	Tracy Marshbanks Sells 15,391 Shares of ANI Pharmaceuticals Inc (ANIP) Stock www.americanbankingnews.com - March 12 at 10:28 PM
	Tracy Marshbanks Sells 64,221 Shares of ANI Pharmaceuticals Inc (ANIP) Stock www.americanbankingnews.com - March 12 at 10:28 PM
	ANI Pharmaceuticals Inc (ANIP) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - March 10 at 1:28 AM
	Wired News – Aptose Biosciences Inked Exclusive License Agreement with OHM Oncology for APL-581 finance.yahoo.com - March 9 at 9:22 AM
	ANI Pharmaceuticals (ANIP) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow seekingalpha.com - March 8 at 5:52 PM
	Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 4,177 Shares of Stock www.americanbankingnews.com - March 7 at 6:50 PM
	ANI Pharmaceuticals Inc (ANIP) Holdings Increased by Ranger Investment Management L.P. www.americanbankingnews.com - March 6 at 2:11 PM
	Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 28,652 Shares of Stock www.americanbankingnews.com - March 5 at 6:22 PM
	ANI Pharmaceuticals (ANIP) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 3 at 6:07 PM
	ANI Pharmaceuticals to Present at the Raymond James 39th Annual Institutional Investors Conference finance.yahoo.com - March 2 at 8:56 AM
	Globeflex Capital L P Has $1.84 Million Position in ANI Pharmaceuticals Inc (ANIP) www.americanbankingnews.com - March 1 at 5:08 PM
	Cortina Asset Management LLC Takes $6.09 Million Position in ANI Pharmaceuticals Inc (ANIP) www.americanbankingnews.com - March 1 at 11:53 AM
	ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q4 2017 Results - Earnings Call Transcript seekingalpha.com - February 27 at 5:23 PM
	ANI Pharmaceuticals, Inc. to Host Earnings Call finance.yahoo.com - February 27 at 5:23 PM
	ANI Pharmaceuticals (ANIP) Issues Quarterly Earnings Results www.americanbankingnews.com - February 27 at 11:30 AM
	ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance finance.yahoo.com - February 27 at 9:01 AM
	ANI Pharmaceuticals (ANIP) Issues FY18 Earnings Guidance www.americanbankingnews.com - February 27 at 8:48 AM
	ANI Pharmaceuticals (ANIP) Downgraded by BidaskClub to "Sell" www.americanbankingnews.com - February 25 at 6:03 PM
	ANI Pharmaceuticals (ANIP) Cut to "C+" at TheStreet www.americanbankingnews.com - February 25 at 12:56 PM
	$52.49 Million in Sales Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter www.americanbankingnews.com - February 25 at 2:02 AM
	Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) to Announce $1.09 Earnings Per Share www.americanbankingnews.com - February 23 at 9:14 PM
	ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 Guidance finance.yahoo.com - February 20 at 8:47 AM
	Investors Are Undervaluing ANI Pharmaceuticals Inc (NASDAQ:ANIP) By 39.62%, Here Is My Intrinsic Value Calculation finance.yahoo.com - February 14 at 9:27 AM
	ANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - February 13 at 1:38 AM
	Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) Will Post Earnings of $1.09 Per Share www.americanbankingnews.com - February 6 at 9:12 PM
	ANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $1.09 Per Share www.americanbankingnews.com - January 21 at 1:16 AM
	ANI Pharmaceuticals Inc (ANIP) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - January 19 at 1:32 AM
	ANI Pharmaceuticals (ANIP) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - January 6 at 12:30 PM
	INC Research (INCR) versus ANI Pharmaceuticals (ANIP) Head to Head Comparison www.americanbankingnews.com - January 4 at 7:30 PM
	$1.09 EPS Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter www.americanbankingnews.com - January 4 at 3:28 AM
	Top-Rated Stocks: ANI Pharmaceuticals Sees Composite Rating Climb To 97 finance.yahoo.com - January 3 at 11:00 AM
	ANI Pharmaceuticals (ANIP) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - January 2 at 5:56 PM

ANI Pharmaceuticals (NASDAQ:ANIP) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

ANI Pharmaceuticals (NASDAQ:ANIP) Income Statement, Balance Sheet and Cash Flow Statement

ANI Pharmaceuticals (NASDAQ ANIP) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff